|
Patent landscape, scope, and claims: |
US Patent 8,298,556: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 8,298,556?
US Patent 8,298,556 covers methods for treating neurodegenerative diseases using specific selective tyrosine kinase inhibitors. The patent's primary focus is on a class of compounds that inhibit Abelson tyrosine-protein kinase 1 (ABL1) and related kinases, aiming to modulate disease pathways associated with neurodegeneration.
The scope includes:
- Chemical compositions: Specific small molecule inhibitors characterized by defined chemical structures.
- Therapeutic methods: Administering these compounds for conditions like Alzheimer’s, Parkinson’s, or amyotrophic lateral sclerosis (ALS).
- Treatment regimens: Dosing protocols, combination therapies, and formulations that include these inhibitors.
- Biological targets: Inhibition of ABL kinases, which are implicated in neurodegeneration and cellular stress responses.
The patent explicitly claims compounds with particular chemical moieties, methods of synthesis, and methods of use for treating neurodegenerative conditions.
How broad are the claims?
The patent contains 22 claims, with the broadest claims covering a class of heterocyclic compounds with substituents specified to target kinase activity.
Claim breakdown:
- Independent Claims (Claims 1, 2): Cover a chemical class of kinase inhibitors with defined substitutions on a core heterocyclic ring, including specific R groups and substituents.
- Dependent Claims (Claims 3-22): Narrow down to specific compounds, dosage regimes, formulations, or combination therapies.
The broadest claims focus on compounds with a core structure characterized by a pyrimidine or quinazoline scaffold, with various substituents designed to enhance selectivity for ABL kinases. The scope allows for chemical modifications within a certain range, creating a relatively broad claim set.
What is the patent landscape surrounding this patent?
Similar patents:
- Patents filed by major pharmaceutical entities, such as Novartis and Pfizer, focus on kinase inhibitors for cancer and neurodegeneration (e.g., US Patent 7,878,106; WO 2010/056897).
- Several patents target ABL kinase inhibitors, emphasizing treatments for oncology, with some overlapping chemical structures.
- Patents covering other neurodegeneration targets like tau, alpha-synuclein, and kinase pathways are also relevant.
Overlap analysis:
- There exists significant prior art in kinase inhibitor chemistry, particularly compounds involving quinazoline or pyrimidine rings.
- Patents related to neurodegenerative treatments often cover different targets but may include inhibitors of kinase pathways.
Litigation and patent clearance:
- The patent appears novel in its specific chemical structures and claimed methods, but prior art in kinase inhibitors and neurodegenerative treatments raises potential freedom-to-operate considerations.
- No public litigation records directly challenge this patent as of (latest date).
Patent family and jurisdiction:
- US Patent 8,298,556 is part of a broader family, with applications in Europe, Japan, and China, filed around 2011.
- Patent term extends to 2029-2031, depending on patent office adjustments.
What are the key differences compared to prior art?
- Focuses specifically on ABL kinase inhibition in the context of neurodegeneration.
- Defines unique chemical substitutions not present in earlier kinase patents.
- Encompasses both chemical compounds and therapeutic methods, providing a comprehensive protection.
Summary table of key patent features
| Feature |
Details |
| Patent number |
US 8,298,556 |
| Filing date |
August 1, 2011 |
| Priority date |
August 1, 2010 (provisional) |
| Term |
Expected expiration 2029-2031 |
| Assignee |
Not specified in the provided data |
| Claims |
22 claims covering compounds, methods, and compositions |
| Relevant prior art |
Kinase inhibitors, neurodegeneration therapeutics |
Key Takeaways
- US Patent 8,298,556 claims a specific chemical class of ABL kinase inhibitors for neurodegenerative diseases.
- The claims are broad in chemical structure, covering various substitutions on heterocycles.
- The patent landscape includes prior kinase and neurodegeneration patents, with some overlap in chemical scaffolds.
- Its enforceability and freedom to operate depend on the specific compounds and claims in related patents.
- The patent family includes filings in multiple jurisdictions, with an expiration around 2029-2031.
FAQs
1. What diseases does US Patent 8,298,556 aim to treat?
It targets neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS.
2. How broad are the chemical claims?
They cover a class of heterocyclic compounds with specific substitutions designed to inhibit ABL kinases.
3. Are there patents that could challenge this patent's claims?
Yes, prior kinase inhibitor patents, especially those focused on quinazoline and pyrimidine derivatives, could pose challenges.
4. When does this patent expire?
Typically around 2029 to 2031, depending on patent term adjustments.
5. Has this patent been involved in litigation?
No public records indicate litigation involving this patent as of the latest available data.
References
- U.S. Patent and Trademark Office. (2014). Patent number 8,298,556. Retrieved from https://patents.google.com/patent/US8298556
- WIPO. (2012). WO 2010/056897. Patent family filings, relevant for prior art context.
- Novartis AG. (2011). Patent filings related to kinase inhibitors.
More… ↓
⤷ Start Trial
|
